SOPHiA GENETICS SA (NASDAQ:SOPH) Stock Holdings Increased by Federated Hermes Inc.

Federated Hermes Inc. lifted its stake in SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) by 89.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 189,000 shares of the company's stock after purchasing an additional 89,000 shares during the quarter. Federated Hermes Inc. owned 0.28% of SOPHiA GENETICS worth $627,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. Dimensional Fund Advisors LP lifted its position in shares of SOPHiA GENETICS by 23.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company's stock worth $68,000 after purchasing an additional 4,115 shares in the last quarter. Silverberg Bernstein Capital Management LLC lifted its stake in SOPHiA GENETICS by 54.4% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 34,675 shares of the company's stock valued at $115,000 after acquiring an additional 12,211 shares during the last quarter. Ridgewood Investments LLC lifted its stake in SOPHiA GENETICS by 1,930.5% in the first quarter. Ridgewood Investments LLC now owns 40,610 shares of the company's stock valued at $135,000 after acquiring an additional 38,610 shares during the last quarter. Bank Pictet & Cie Europe AG lifted its stake in SOPHiA GENETICS by 14.4% in the first quarter. Bank Pictet & Cie Europe AG now owns 255,200 shares of the company's stock valued at $847,000 after acquiring an additional 32,200 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in SOPHiA GENETICS by 6.5% in the fourth quarter. Millennium Management LLC now owns 698,634 shares of the company's stock valued at $2,180,000 after acquiring an additional 42,689 shares during the last quarter. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS Price Performance

NASDAQ SOPH opened at $3.20 on Friday. The company has a quick ratio of 2.94, a current ratio of 3.39 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $213.40 million, a PE ratio of -7.27 and a beta of 1.00. The company has a 50 day moving average price of $3.23 and a two-hundred day moving average price of $3.27. SOPHiA GENETICS SA has a 12-month low of $2.58 and a 12-month high of $4.92.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.58. The firm had revenue of $18.32 million during the quarter, compared to analysts' expectations of $17.49 million. SOPHiA GENETICS had a negative net margin of 40.99% and a negative return on equity of 30.69%. As a group, equities analysts predict that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

SOPHiA GENETICS Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.